Iterum Therapeutics plc
ITRM
$1.03
-$0.05-4.63%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 254.00K | -- | -- | -- | -- |
| Gross Profit | -254.00K | -- | -- | -- | -- |
| SG&A Expenses | 7.98M | 7.55M | 7.61M | 7.56M | 7.48M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.70M | 26.46M | 38.26M | 45.10M | 47.47M |
| Operating Income | -18.70M | -26.46M | -38.26M | -45.10M | -47.47M |
| Income Before Tax | -24.53M | -30.20M | -27.96M | -35.05M | -37.76M |
| Income Tax Expenses | 240.00K | 357.00K | 382.00K | 538.00K | 613.00K |
| Earnings from Continuing Operations | -24.77 | -30.55 | -28.34 | -35.58 | -38.37 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.77M | -30.55M | -28.34M | -35.58M | -38.37M |
| EBIT | -18.70M | -26.46M | -38.26M | -45.10M | -47.47M |
| EBITDA | -18.41M | -25.99M | -37.36M | -43.78M | -45.72M |
| EPS Basic | -1.31 | -2.00 | -2.00 | -2.64 | -2.96 |
| Normalized Basic EPS | -0.81 | -1.24 | -1.23 | -1.63 | -1.82 |
| EPS Diluted | -1.31 | -2.00 | -2.00 | -2.64 | -2.96 |
| Normalized Diluted EPS | -0.81 | -1.24 | -1.23 | -1.63 | -1.82 |
| Average Basic Shares Outstanding | 78.72M | 65.21M | 58.20M | 54.60M | 51.84M |
| Average Diluted Shares Outstanding | 78.72M | 65.21M | 58.20M | 54.60M | 51.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |